Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After Transplant
← catalyst calendarNCT05317416 · readout in 349 d
Sponsored by Pfizer (industry) · PFE — their whole pipeline →.
Phase
Phase 3
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
854actual
Sites
209
Countries
Australia, Austria, Belgium +24
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2022-03-25 | actual | When the study began enrolling |
| Primary completion | 2027-08-04 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2029-10-31 | estimated | The whole study's end, after follow-up |
| First posted | 2022-04-07 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-04-16 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Multiple Myeloma
Interventions
- Drug: Elranatamab
- Drug: Lenalidomide
- Drug: Lenalidomide
- Drug: Elranatamab
Primary outcome
what the primary-completion date above is the date OFProgression Free Survival
measured Assessed for up to approximately 5 years
Permalink · PFE's whole pipeline · Catalyst calendar · Every registered study · What changed